Last reviewed · How we verify

GSK1755165; placebo; zopiclone

GlaxoSmithKline · Phase 3 active Small molecule

GSK1755165; placebo; zopiclone is a Non-benzodiazepine hypnotic (Z-drug) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Insomnia (sleep initiation and/or maintenance).

GSK1755165 is a selective GABA-A receptor modulator that enhances inhibitory neurotransmission to promote sleep.

GSK1755165 is a selective GABA-A receptor modulator that enhances inhibitory neurotransmission to promote sleep. Used for Insomnia (sleep initiation and/or maintenance).

At a glance

Generic nameGSK1755165; placebo; zopiclone
SponsorGlaxoSmithKline
Drug classNon-benzodiazepine hypnotic (Z-drug)
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaNeurology / Sleep Medicine
PhasePhase 3

Mechanism of action

GSK1755165 binds to and potentiates GABA-A receptors, increasing the frequency of chloride channel opening and enhancing GABAergic inhibitory signaling in the central nervous system. This mechanism is similar to other Z-drugs like zopiclone (the comparator in this trial), but GSK1755165 was designed with improved selectivity and potentially better tolerability. The drug promotes sleep onset and maintenance through enhanced neuronal inhibition.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK1755165; placebo; zopiclone

What is GSK1755165; placebo; zopiclone?

GSK1755165; placebo; zopiclone is a Non-benzodiazepine hypnotic (Z-drug) drug developed by GlaxoSmithKline, indicated for Insomnia (sleep initiation and/or maintenance).

How does GSK1755165; placebo; zopiclone work?

GSK1755165 is a selective GABA-A receptor modulator that enhances inhibitory neurotransmission to promote sleep.

What is GSK1755165; placebo; zopiclone used for?

GSK1755165; placebo; zopiclone is indicated for Insomnia (sleep initiation and/or maintenance).

Who makes GSK1755165; placebo; zopiclone?

GSK1755165; placebo; zopiclone is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is GSK1755165; placebo; zopiclone in?

GSK1755165; placebo; zopiclone belongs to the Non-benzodiazepine hypnotic (Z-drug) class. See all Non-benzodiazepine hypnotic (Z-drug) drugs at /class/non-benzodiazepine-hypnotic-z-drug.

What development phase is GSK1755165; placebo; zopiclone in?

GSK1755165; placebo; zopiclone is in Phase 3.

What are the side effects of GSK1755165; placebo; zopiclone?

Common side effects of GSK1755165; placebo; zopiclone include Headache, Dizziness, Somnolence, Nausea, Fatigue.

What does GSK1755165; placebo; zopiclone target?

GSK1755165; placebo; zopiclone targets GABA-A receptor and is a Non-benzodiazepine hypnotic (Z-drug).

Related